Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 711 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopic Clear all
Terminated Phase 4 Interventional Results available

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

NCT03539601
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole ointment, 2%, Hydrocortisone butyrate cream, 0.1%, Pimecrolimus cream, 1%, Crisaborole Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Bryant, Arkansas • Encinitas, California • Orange Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 28, 2026, 4:28 AM EDT
Completed Not applicable Interventional Results available

The Effect of Montelukast on Asthma Control in Overweight/Obese Atopic Asthmatics

NCT01329939
View directory record Official record
Conditions
Asthma, Obesity, Inflammation
Interventions
Montelukast, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
7 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 28, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Results available

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

NCT03363854
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 28, 2026, 4:28 AM EDT
Terminated Not applicable Interventional

Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients

NCT02713035
View directory record Official record
Conditions
Dermatitis, Atopic, Eczema
Interventions
Self help intervention
Behavioral
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
4 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 28, 2026, 4:28 AM EDT
Terminated Phase 1 Interventional

A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis

NCT01122914
View directory record Official record
Conditions
Anakinra, Kineret, Atopic Dermatitis, Eczema, Allergic Disease
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 28, 2026, 4:28 AM EDT
Recruiting Phase 2 Interventional

Cardamom and Topical Roseomonas in Atopic Dermatitis

NCT06096857
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Roseomonas mucosa (RSM2015) and Cardamom seeds, Placebo (sucrose)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 28, 2026, 4:28 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens

NCT00557284
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Montelukast, Placebo
Drug
Lead sponsor
1st Allergy & Clinical Research Center
Other
Eligibility
1 Year to 8 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Centennial, Colorado • Thornton, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Oct 28, 2026, 4:28 AM EDT
Terminated Phase 2 Interventional Results available

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

NCT03809663
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tezepelumab, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Fountain Valley, California • Santa Monica, California • Alpharetta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 28, 2026, 4:28 AM EDT
Completed Not applicable Interventional

An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

NCT06275659
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
CT-100-004-A, CT-100-004-B
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 28, 2026, 4:28 AM EDT
Terminated No phase listed Observational

Asthma, Missed Immunizations, and Vitamin D Deficiency in Atopic Dermatitis

NCT01234909
View directory record Official record
Conditions
Atopic Dermatitis, Vitamin D Deficiency, Asthma
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 18 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 28, 2026, 4:28 AM EDT
Not listed Phase 3 Interventional

Metal Panel Allergen Patch Test Study

NCT04500834
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Metal Panel T.R.U.E. Test
Biological
Lead sponsor
Allerderm
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 28, 2026, 4:28 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

NCT07734415
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
Interventions
IMG-007
Drug
Lead sponsor
Inmagene LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
16
States / cities
Lancaster, California • Los Angeles, California • Ocala, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 28, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics

NCT00784459
View directory record Official record
Conditions
Atopic Asthma
Interventions
abatacept, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Oct 28, 2026, 4:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bathing Babies and Allergy

NCT03050658
View directory record Official record
Conditions
Atopic Dermatitis, Allergy
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
0 Hours to 72 Hours
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 28, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)

NCT02564055
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
GSK2894512 1% Cream, GSK2894512 0.5% Cream, Vehicle cream
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
36
States / cities
Fort Smith, Arkansas • Fresno, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 28, 2026, 4:28 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Role of Bacterial Toxins in Human Skin Disease

NCT02910791
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 28, 2026, 4:28 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

NCT06863961
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Fremont, California • Los Angeles, California • Fort Myers, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 28, 2026, 4:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects

NCT00620230
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
NVP-VAK694
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
North Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2010 · Synced Oct 28, 2026, 4:28 AM EDT
Completed Not applicable Interventional

The Effect of Isosorbide Diesters Based Moisturizer on Skin Health

NCT04831892
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal, Moisturizer containing Colloidal Oatmeal only
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 28, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

NCT04444752
View directory record Official record
Conditions
Moderate-to-severe Atopic Dermatitis
Interventions
CBP-201, placebo
Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
38
States / cities
Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 28, 2026, 4:28 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 4:28 AM EDT
Not listed Phase 2 Interventional

Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

NCT04296864
View directory record Official record
Conditions
Atopic Keratoconjunctivitis
Interventions
Dupilumab
Drug
Lead sponsor
Andover Eye Associates
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
20
States / cities
Los Angeles, California • Littleton, Colorado • Hollywood, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 28, 2026, 4:28 AM EDT
Completed Not applicable Interventional

Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments

NCT03051347
View directory record Official record
Conditions
Atopic Dermatitis, Ichthyosis, Psoriasis
Interventions
Itch Questionnaire and Interview, Stigma Questionnaire and Interview, Cognitive Interview and PROMIS Itch Questionnaire
Other
Lead sponsor
Northwestern University
Other
Eligibility
0 Years to 17 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 28, 2026, 4:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Histamine Pharmacogenetics in Children With Atopic Dermatitis

NCT00277433
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Buccal Swab
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Months to 5 Years
Enrollment
751 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
7
States / cities
Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 28, 2026, 4:28 AM EDT